MRI allows for earlier detection of the joint synovitis, erosions, and bone marrow edema present in inflammatory arthritis, facilitating earlier diagnosis and treatment… Read More
Recent advances in drug therapies for rheumatoid arthritis (RA) have increased the importance of early intervention. Several serological testing and imaging techniques help facilitate early diagnosis… Read More
A 65-year-old woman, who was confined to a wheelchair because of severe rheumatoid arthritis, was concerned about nodules that had erupted on her fingers and hands during the previous 3 weeks… Read More
A 50 year-old physician experienced the abrupt onset of tenderness and swelling in the distal interphalangeal (DIP) joint of his right index finger. His only significant past medical history was Wolf-Parkinson-White syndrome… Read More
(AUDIO) Anxiety is even more common than depression among people who have arthritis, a new study has shown. Here to discuss the implications for diagnosis and treatment is Eilzabeth Lin MD, a family medicine physician who is a longstanding researcher in the field of depression and pain.
Treatment of patients with rheumatoid arthritis (RA) has undergone tremendous advances related to greater understanding of its pathophysiology and the introduction of effective disease-modifying medications.
Publication of the American College of Rheumatology recommendations for treating patients who have rheumatoid arthritis (RA) with biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) had a minimal effect on prescribing practices.
For patients with early rheumatoid arthritis (RA), structured treatment programs in early arthritis clinics are more effective in improving activity and preventing major radiographic progression than nonprotocolized referral and follow-up.
Interleukin-6 (IL-6) inhibition with tocilizumab (TCZ) plus methotrexate (MTX) retards joint damage progression independently of its impact on disease activity in patients with rheumatoid arthritis (RA).
Six rheumatoid arthritis disease activity measures have been recommended for use in US clinical practice by an American College of Rheumatology working group, the organization announced.
New recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of patients with rheumatoid arthritis have been released by the American College of Rheumatology.
Rheumatoid arthritis (RA) is a progressive immune-mediated disease involving the synovium that can culminate in joint destruction, significant functional impairment, and early mortality.
For patients with early rheumatoid arthritis (RA), structured treatment programs in early arthritis clinics are more effective in improving activity and preventing major radiographic progression than nonprotocolized referral and follow-up. More »
Publication of the American College of Rheumatology recommendations for treating patients who have rheumatoid arthritis (RA) with biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) had a minimal effect on prescribing practices. More »
Treatment of patients with rheumatoid arthritis (RA) has undergone tremendous advances related to greater understanding of its pathophysiology and the introduction of effective disease-modifying medications. More »
PLoS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.
Both murine and human genome-wide association studies have implicated peptidyl arginine deiminase (PAD4) as a susceptibility gene in rheumatoidarthritis (RA). In addition, patients with RA commonly have autoantibodies which recognize PAD4 or and/or citrullinated peptides. This study aims to evaluate the role of PAD4 in the effector phase of arthritis.|Both murine and human genome-wide association studies have implicated peptidyl arginine deiminase (PAD4) as a susceptibility gene in rheumatoidarthritis (R
Gliostatin/thymidine phosphorylase (GLS/TP) has angiogenic and arthritogenic activities, and aberrant GLS production has been observed in the active synovial membranes of rheumatoidarthritis (RA) patients. The human GLS gene promoter contains at least seven consensus binding sites for the DNA binding protein Sp1. Here we examined whether Sp1 is necessary for GLS production in RA. We also studied the effects of the Sp1 inhibitor mithramycin on GLS production in RA fibroblast-like synoviocytes (FLSs). |Glio
Gliostatin/thymidine phosphorylase (GLS/TP) has angiogenic and arthritogenic activities, and aberrant GLS production has been observed in the active synovial membranes of rheumatoidarthritis (RA) patients. The human GLS gene promoter contains at least seven consensus binding sites for the DNA binding protein Sp1. Here we examined whether Sp1 is necessary for GLS production in RA. We also studied the effects of the Sp1 inhibitor mithramycin on GLS production in RA fibroblast-like synoviocytes (FLSs). |Glio
Physician Performance Goals Are Great, But Balance Is More Realistic Jennifer Frank, MD, May 15, 2012 Performance measurements for physicians are well-intentioned and get me to rethink how I practice. But in the end I won't make the goals, so I'll have to go with balance over perfection.
Designing the Perfect Business Card for Your Medical Practice C. Noel Henley, MD, May 11, 2012 Does your business card say anything substantive about the valuable work you do in your practice? Here’s how to re-design your next business card for maximum impact and engagement.
Registered Nurses an Ideal Fit for Primary Care Practices Audrey "Christie" McLaughlin, RN, May 10, 2012 Here are four good reasons to hire a registered nurse for your primary care practice …maybe even instead of a medical assistant.
The Five Biggest Medical Practice Marketing Mistakes James Doulgeris, May 10, 2012 There are best practices to marketing your practice, but often, success is more about knowing what not to do. Here are the five most common pitfalls …and how to avoid them.
Can You Practice Medicine and Manage Your Practice? Rosemarie Nelson, May 9, 2012 Whether you practice alone, or in a group, if you're trying to see patients in this pay-for-volume environment and also run the business of your practice, you may be missing out on important opportunities.
The armamentarium of treatment modalities available to physicians seeing patients with rheumatoid arthritis (RA) and other forms of inflammatory arthritis has increased dramatically in recent years. In particular, the introduction of the biologic disease-modifying antirheumatic drugs (DMARDs), most notably the tumor necrosis factor a (TNF-a) inhibitors, has afforded clinicians new opportunities to mitigate disease progression.
Rheumatoid arthritis (RA) often presents late, when irreversible damage has occurred. More than half of primary care consultations are for joint pain, but the average time from initial presentation with symptoms to confirmation of diagnosis of RA is 18 weeks.
(AUDIO) Anxiety is even more common than depression among people who have arthritis, a new study has shown. Here to discuss the implications for diagnosis and treatment is Eilzabeth Lin MD, a family medicine physician who is a longstanding researcher in the field of depression and pain.
